<?xml version="1.0" encoding="UTF-8"?>
<p id="p0030">The present COVID-19 pandemic caused by the coronavirus SARS-CoV-2 is yet another example of the dramatic impact of emerging viral infections on human morbidity and mortality worldwide. Currently, no specific drug for the new coronavirus is available and repurposing is the only strategy in place [
 <xref rid="bib1" ref-type="bibr">1</xref>]. Clearly, there is an urgent need for drugs active against a wider number of viruses to contain future emergencies early on. Host directed therapy aims at targeting essential host factors for viral replication and triggering immune antiviral pathways [
 <xref rid="bib2" ref-type="bibr">2</xref>]. Advantages of this approach include not only the possibility of targeting multiple viruses, but also an increased threshold to the emergence of resistance.
</p>
